GSK confirms post-Brexit UK still attractive, with £275 million in manufacturing network

27 July 2016

GlaxoSmithKline (LSE: GSK), Britain’s largest pharma company, this morning announced £275 million ($360 million) of new investments at three of its manufacturing sites in the UK to boost production and support delivery of its latest innovative respiratory and large molecule biological medicines.

The vast majority of these products will be for export to global markets, said the company which, along with the vast majority of the pharmaceutical and biotechnology industrialists, warned of the dangers that the UK would face in the event of the nation voting to leave the European Union.

GSK, which is due to report second-quarter financial results later today, clearly believes that the UK remains “an attractive location” despite Brexit. Sterling has fallen 10% against the dollar and the euro since the referendum result on June 24, thus there is the benefit of a cheaper pound when producing products bound for foreign markets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK